[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2002258T - Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas - Google Patents

Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas

Info

Publication number
PT2002258T
PT2002258T PT77532265T PT07753226T PT2002258T PT 2002258 T PT2002258 T PT 2002258T PT 77532265 T PT77532265 T PT 77532265T PT 07753226 T PT07753226 T PT 07753226T PT 2002258 T PT2002258 T PT 2002258T
Authority
PT
Portugal
Prior art keywords
gelsolin
multiple sclerosis
treat multiple
neurologic diseases
diagnose
Prior art date
Application number
PT77532265T
Other languages
English (en)
Inventor
P Stossel Thomas
Lee Po-Shun
Dittel Bonnie
Maresz Katarzyna
Original Assignee
The Brigham And Women`S Hospital Inc
Bloodcenter Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women`S Hospital Inc, Bloodcenter Res Foundation Inc filed Critical The Brigham And Women`S Hospital Inc
Publication of PT2002258T publication Critical patent/PT2002258T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
PT77532265T 2006-03-15 2007-03-14 Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas PT2002258T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78250906P 2006-03-15 2006-03-15

Publications (1)

Publication Number Publication Date
PT2002258T true PT2002258T (pt) 2017-12-18

Family

ID=38510104

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77532265T PT2002258T (pt) 2006-03-15 2007-03-14 Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas

Country Status (11)

Country Link
US (2) US8440622B2 (pt)
EP (1) EP2002258B1 (pt)
JP (2) JP2009530613A (pt)
CN (1) CN101460843B (pt)
CA (1) CA2680333C (pt)
DK (1) DK2002258T3 (pt)
ES (1) ES2651619T3 (pt)
HU (1) HUE035980T2 (pt)
PL (1) PL2002258T3 (pt)
PT (1) PT2002258T (pt)
WO (1) WO2007106577A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694342B1 (en) * 2003-11-12 2020-11-04 Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2860173C (en) * 2004-05-12 2021-12-14 The Brigham And Women's Hospital, Inc. Determining plasma gelsolin level to predict risk of developing infection
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
DK3279663T3 (da) 2006-03-15 2021-10-18 Brigham & Womens Hospital Inc Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
WO2009124226A2 (en) * 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Gelsolin uses in neurological disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
EP3279668B1 (en) * 2010-12-16 2019-05-15 National Institute of Advanced Industrial Science and Technology Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
EP3118325B1 (en) * 2014-03-11 2019-07-24 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Blood disease diagnosis
FR3036188B1 (fr) * 2015-05-12 2019-06-07 Biomerieux Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
JP7101252B2 (ja) * 2018-03-05 2022-07-14 アカデミア シニカ 末梢神経障害を診断及び／又は治療するための方法及びキット
AU2021347408A1 (en) * 2020-09-23 2023-05-04 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627353A (en) * 1899-06-20 Cis robinson
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
AU663050B2 (en) 1990-04-11 1995-09-28 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
AU8086191A (en) 1990-05-04 1991-11-27 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
ES2183220T3 (es) 1996-12-04 2003-03-16 Renovo Ltd Curacion de heridas y tratamientos de la fibrosis.
AU7100898A (en) 1997-04-02 1998-10-22 Brigham And Women's Hospital Means of ascertaining an individual's risk profile for atherosclerotic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6409599B1 (en) 1999-07-19 2002-06-25 Ham On Rye Technologies, Inc. Interactive virtual reality performance theater entertainment system
AU2002225219A1 (en) * 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
AU2003296875B2 (en) 2002-02-06 2008-01-24 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
AU2003226401A1 (en) 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CA2527916A1 (en) 2003-03-14 2004-09-30 Aaron B. Kantor Biological markers for diagnosing rheumatoid arthritis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP1694342B1 (en) 2003-11-12 2020-11-04 Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2860173C (en) 2004-05-12 2021-12-14 The Brigham And Women's Hospital, Inc. Determining plasma gelsolin level to predict risk of developing infection
EP3130349A1 (en) * 2004-06-04 2017-02-15 Genentech, Inc. Method for treating multiple sclerosis
EP1929297B1 (en) 2005-09-29 2012-11-21 Caprion Proteomics USA, LLC Biomarkers for multiple sclerosis and methods of use thereof
DK3279663T3 (da) 2006-03-15 2021-10-18 Brigham & Womens Hospital Inc Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用

Also Published As

Publication number Publication date
CA2680333A1 (en) 2007-09-20
CN101460843A (zh) 2009-06-17
US20100021428A1 (en) 2010-01-28
EP2002258B1 (en) 2017-09-27
WO2007106577A2 (en) 2007-09-20
JP2009530613A (ja) 2009-08-27
DK2002258T3 (en) 2018-01-02
JP6203995B2 (ja) 2017-09-27
CN101460843B (zh) 2018-06-22
JP2012053071A (ja) 2012-03-15
US20130230455A1 (en) 2013-09-05
WO2007106577A3 (en) 2008-10-16
ES2651619T3 (es) 2018-01-29
PL2002258T3 (pl) 2018-06-29
CA2680333C (en) 2016-10-25
US8440622B2 (en) 2013-05-14
EP2002258A2 (en) 2008-12-17
HUE035980T2 (hu) 2018-06-28
EP2002258A4 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
PT2002258T (pt) Utilização de gelsolina para o tratamento da esclerose múltipla e para o diagnóstico de doenças neurológicas
HK1250781A1 (zh) 在診斷和治療炎性疾病上凝溶膠蛋白的應用
HK1256238A1 (zh) 用那他珠單抗治療炎性疾病和自身免疫疾病的方法
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
SI2676967T1 (sl) Metode zdravljenja vnetne in avtoimunske bolezni z natalizumabom
HK1127553A1 (en) Use of pegylated il-10 to treat cancer
HK1131047A1 (en) Treatment of inflammatory diseases
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
PT2056842E (pt) Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
EP2111230A4 (en) COMMON ADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATING AGENT TO TREAT MULTIPLE SCLEROSE
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
EP2021016A4 (en) CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0608647D0 (en) Methods of diagnosis and treatment
EP2061788A4 (en) NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED LYMPHOCYTES
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
PL2012814T3 (pl) Sposoby leczenia chorób autoimmunologicznych
ZA201105320B (en) Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
GB0602110D0 (en) Use of ultrasound in the diagnosis and treatment of multiple sclerosis
EP2054080A4 (en) TREATMENT AND PREVENTION OF ALLERGIC RESPIRATORY DISEASES
PL1927351T3 (pl) Zastosowanie agomelatyny do wytwarzania leku przeznaczonego do leczenia leukomalacji okołokomorowej
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
AP2721A (en) Use of cantffln-6-one and its analogues in the treatment of pathologies linked to mycobacteria
IL188007A0 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
SI2012814T1 (sl) Postopki za zdravljenje avtoimunskih bolezni
TWM300093U (en) Improved structure of body cleansing appliance